Indian IT and pharma stocks are not benefiting from a weaker rupee as expected. Tariff concerns are overshadowing currency gains. Investors are waiting for clarity on trade deals. Foreign investors have also been selling these stocks. Valuations remain a concern for pharma companies. Demand for IT services shows signs of improvement. Stock selection will be crucial for investors.
RBI to focus on managing INR volatility over liquidity: Tanvee Gupta Jain
The Reserve Bank of India faces a challenging policy review. Global uncertainties and volatile oil prices are key concerns. Experts highlight rising external risks and